{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-225369","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2026-05-15T12:03:20+00:00","discovered_at":"2026-05-15T12:05:00.218088+00:00","generated_at":"2026-05-15T12:05:31.805444+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MiNK Q1 cash $9.5M, net loss $2.7M; initiates randomized Phase 2 for agenT-797 in ARDS","bullets":["Cash $9.5M at Mar 31 (down from $13.4M at Dec 31); repaid $5.2M Agenus convertible note.","Net loss $2.7M ($0.57/sh) vs $2.8M ($0.70/sh) year ago; raised $3.0M via ATM in Q1.","Initiated randomized Phase 2 trial of agenT-797 in severe acute lung injury/ARDS; data expected H2 2026.","Non-dilutive C-Further collaboration provides up to $1.1M for PRAME-targeted iNKT therapy in pediatric cancers.","Upcoming ATS presentation May 20 on agenT-797 for coccidioides infection; NIH-funded GvHD program ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-225369","json":"https://secwatch.observer/filing/0001193125-26-225369.json","markdown":"https://secwatch.observer/filing/0001193125-26-225369.md","text":"https://secwatch.observer/filing/0001193125-26-225369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000119312526225369/0001193125-26-225369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000119312526225369/inkt-20260515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:05:31.805444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac925316416ef3823e1cff430f7b936153f689bc","claim":"MiNK Therapeutics, Inc. reported financial results for the first quarter ending March 31, 2026.","evidence_excerpt":"On May 15, 2026, MiNK Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000119312526225369/0001193125-26-225369-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ending March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}